Innovative Biopharmaceutical Compound Synthesis
Heparinex, L.L.C. is a biopharmaceutical company focused on the novel recombinant synthesis of compounds for (1) the growing anticoagulation market and associated markets and (2) the dermal filler market. Leading carbohydrate chemist/glycobiologist Dr. Paul DeAngelis originally discovered and patented Heparinex’s core technology platforms of proprietary carbohydrate production.
The company’s core platforms employ:
Commercial Applications in Multiple High-Yield Industries
Heparinex’s proprietary carbohydrate production platform technologies provide applications for multiple high-yield industries including:
Heparinex is actively pursuing collaborative partnerships in the specific areas of medical device coatings; novel autoimmune/infectious disease/cancer drug discovery; and dermal fillers.
To learn more about Heparinex, click here to download the company fact sheet.